Kaland DA, Dores GM, Nayernama A, Camilli S, et al. U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome. Clin Lung Cancer 2022;23:e556-e562.
PMID: 36151005